MedPage Today -- An everolimus-eluting stent (Xience) produced better clinical outcomes than a second-generation, paclitaxel-eluting competitor (Taxus) in a large head-to-head trial, researchers said.
MedPage Today -- An everolimus-eluting stent (Xience) produced better clinical outcomes than a second-generation, paclitaxel-eluting competitor (Taxus) in a large head-to-head trial, researchers said.